Cushing’s syndrome patients to receive safer drug options
22 February 2012
FDA approves first Cushing’s syndrome drug, Corcept’s Korlym
20 February 2012
Showing 1-4 of 4 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
